Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

• Status: RECRUITING
• Trial end date: 2031-12-31

Summary

To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

• Phase: PHASE2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Pfizer
• Treatments: Busulfan; Granulocyte Colony-Stimulating Factor; Lenalidomide; Melphalan; plerixafor; Stem Cell Transplantation